IQV

NYSE·Healthcare·Medical - Diagnostics & Research·USA

Latest market price

208.05

+0.73+0.35%

Overview Short InterestFilings

IQVQT57IQVIA Holdings Inc.·NYSE

Overview Short InterestFilings

208.05+0.35%

News

Up 0.4% — IQVIA Gears Up to Report Q2 Earnings: What's in the Offing? (zacks.com).

Medium confidence

Loading chart...

Screen all →

NTRA-1.02%$261.99 A-0.84%$138.57 ILMN-1.41%$194.09 IDXX+0.92%$544.32 MTD-0.35%$1327.18 DGX-0.02%$227.86 WAT-2.02%$374.68 LH+1.98%$296.77

Snapshot

Index

S&P 500

P/E

25.56

EPS (ttm)

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-13-26	Reiterated	Mizuho	Outperform	$215 → $230
Jul-09-26	Reiterated	Deutsche Bank	Buy	$270 → $240
Jul-06-26	Reiterated	HSBC	Buy	$210 → $240
Jul-01-26	Reiterated	Robert W. Baird		$230 → $249
Jun-17-26	Downgrade	Morgan Stanley	Overweight → Equal Weight	$225 → $200
Jun-03-26	Reiterated	HSBC	Buy	$240 → $210
May-07-26	Reiterated	Morgan Stanley	Overweight	$240 → $225
Apr-08-26	Reiterated	Evercore ISI Group	Outperform	$225 → $185
Mar-09-26	Upgrade	TD Cowen	Hold → Buy
Mar-06-26	Upgrade	Barclays	Equal Weight → Overweight

Company

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	16,632	16,310	15,405	14,984	14,410	13,874	11,359	11,088	10,412
Cost of Goods Sold Incl. D&A	12,289	12,024	10,030	9,745	9,382	9,233	7,500	7,300	6,746
Gross Profit	4,343	4,286	5,375	5,239	5,028	4,641	3,859	3,788	3,666
Selling, General and Administrative Excl. Other	1,993	1,999	1,992	2,053	2,071	1,964	1,789	1,734	1,716
Research and Development	0	0	0	0	0	0	0	0	0
Other Operating Expense	45	0	1,181	1,209	1,158	1,284	1,339	1,277	1,209
Operating Income	2,305	2,287	2,202	1,977	1,799	1,393	731	777	741
Interest Expense	756	729	670	672	416	375	416	447	414
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	82	55	137	154	-32	116	65	13	16
Net Income Before Taxes	1,631	1,613	1,669	1,459	1,351	1,134	380	343	343
Income Taxes	250	252	296	101	260	163	72	116	59
Consolidated Net Income	1,385	1,360	1,373	1,358	1,091	966	279	191	259
Net Income From Continuing Operations	1,381	1,361	1,373	1,358	1,091	971	308	227	284
Net Income	1,385	1,360	1,373	1,358	1,091	966	279	191	259
EPS (Recurring)	8.14	7.91	7.57	7.39	5.82	5.05	1.46	0.98	1.27
EPS (Basic, Before Extraordinaries)	8.14	7.91	7.57	7.39	5.82	5.05	1.46	0.98	1.27
EPS (Diluted)	8.07	7.84	7.49	7.29	5.72	4.95	1.43	0.96	1.24
EBITDA	3,519	3,464	3,453	3,256	2,909	2,767	2,076	2,001	1,883
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	25.78	28.75	26.24	31.74	35.82	57.00	125.29	160.95	93.69
Price To Sales Ratio	2.10	2.38	2.31	2.84	2.67	3.88	3.01	2.72	2.28
Gross Margin	26.11	26.28	34.89	34.96	34.89	33.45	33.97	34.16	35.21
Operating Margin	13.86	14.02	14.29	13.19	12.48	10.04	6.44	7.01	7.12
Net Margin	8.33	8.34	8.91	9.06	7.57	6.96	2.46	1.72	2.49
Shares Outstanding	168	172	181	184	188	191	191	195	204
Market Capitalization	34,952	38,771	35,568	42,574	38,519	53,889	34,221	30,129	23,699
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BOUSBIB ARI	See Remarks	Dec 18 '25	Option Exercise	59.90	50,000	2,995,000	857,163	Dec 19
BOUSBIB ARI	See Remarks	Dec 18 '25	Sale	222.43	36,564	8,132,931	820,599	Dec 19
BOUSBIB ARI	See Remarks	Oct 29 '25	Sale	220.33	56,557	12,461,120	828,198	Oct 31
Sherbet Eric	See Remarks	Oct 29 '25	Option Exercise	131.82	10,000	1,318,200	31,108	Oct 31
Sherbet Eric	See Remarks	Oct 29 '25	Sale	219.70	4,000	878,800	27,108	Oct 31
BOUSBIB ARI	See Remarks	Oct 29 '25	Option Exercise	59.90	77,592	4,647,761	884,755	Oct 31
Sherbet Eric	See Remarks	Jul 23 '25	Option Exercise	97.20	11,870	1,153,764	32,978	Jul 25
Sherbet Eric	See Remarks	Jul 23 '25	Sale	190.05	5,800	1,102,290	27,178	Jul 25
Cherofsky Keriann	See Remarks	Jul 23 '25	Sale	191.53	549	105,150	2,910	Jul 25
BOUSBIB ARI	See Remarks	Feb 10 '25	Option Exercise	65.16	40,000	2,606,400	837,083	Feb 12
DANHAKL JOHN G	Director	Dec 03 '24	Buy	200.58	1,275	255,740	1,275	Feb 07
Sherbet Eric	See Remarks	Aug 27 '24	Sale	246.33	1,300	320,229	19,536	Aug 29
BOUSBIB ARI	See Remarks	Mar 01 '24	Option Exercise	65.16	42,847	2,791,911	828,430	Mar 04
BOUSBIB ARI	See Remarks	Mar 01 '24	Sale	250.53	31,678	7,936,193	796,752	Mar 04
STAUB W RICHARD	See Remarks	Feb 29 '24	Sale	247.80	14,100	3,494,033	15,945	Mar 04


Market Cap	34.72B	Forward P/E	14.72	EPS next Y	14.13	Insider Trans	0.00%	Shs Float	158.55M	Perf Month	12.08%


Enterprise Value	48.84B	PEG	2.63	EPS next Q	-	Inst Own	-	Short Float	3.32%	Perf Quarter	29.48%


Income	1.37B	P/S	2.09	EPS this Y	58.75%	Inst Trans	-	Short Ratio	3.20	Perf Half Y	-12.97%


Sales	16.63B	P/B	5.63	EPS next Y	10.31%	ROA	4.67%	Short Interest	5.26M	Perf YTD	-7.70%


Book/sh	-	P/C	12.96	EPS next 5Y	11.20%	ROE	22.46%	52W High	247.06 -15.79%	Perf Year	7.11%


Cash/sh	-	P/FCF	13.64	EPS past 3/5Y	11.08% 40.54%	ROIC	8.42%	52W Low	154.50 34.66%	Perf 3Y	-7.72%


Dividend Est.	-	EV/EBITDA	13.88	Sales past 3/5Y	4.21% 7.50%	Gross Margin	26.11%	Volatility	3.02% 2.99%	Perf 5Y	-16.01%


Dividend TTM	-	EV/Sales	2.94	EPS Y/Y TTM	7.74%	Oper. Margin	13.86%	ATR (14)	6.79	Perf 10Y	185.70%


Dividend Ex-Date	-	Quick Ratio	0.75	Sales Y/Y TTM	7.96%	Profit Margin	8.33%	RSI (14)	61.35	Recom	2.18


Dividend Gr. 3/5Y	-	Current Ratio	0.75	EPS Q/Q	7.41%	SMA20	1.96%	Beta	1.17	Target Price	228.09


Payout	0.00%	Debt/Eq	2.58	Sales Q/Q	8.41%	SMA50	10.91%	Rel Volume	0.67	Prev Close	207.32


Employees	93,000	LT Debt/Eq	2.16	Earnings	Jul 28	SMA200	5.82%	Avg Volume	1.59M	Price	208.05


IPO Date	May 09, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.97% 1.24%	Net Debt/EBITDA	4.01	Volume	1,066,954	Change	0.35%